Cosmetics, Hormones and Pharmacy - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Cosmetics

Hormones

Pharmacy

FDA Warns About Compounded Versions of Ozempic and Wegovy

XTalks

JUNE 5, 2023

Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the GLP-1 hormone released in the gastrointestinal tract after eating. mg and 1 mg doses will be available to wholesalers for distribution to retail pharmacies. Despite this, Novo Nordisk doesn’t anticipate interruptions in supplying 1.7 mg and 2.4

FDA Approval

FDA Approval Containment Drugs Pharmacy

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

Pfizer

DECEMBER 20, 2022

PAXLOVID is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PAXLOVID under 564(b)(1) of the Food Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. IMPORTANT SAFETY INFORMATION. 1 (212) 733-1226 PfizerMediaRelations@pfizer.com.

Drugs

Drugs Licensing Licensing Containment

FDA Warns About Compounded Versions of Ozempic and Wegovy

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

Stay Connected